
Alnylam Announces Partial Buyback of 1.00% Convertible Senior Notes Due 2027
Alnylam Announces Partial Buyback of 1.00% Convertible Senior Notes Maturing in 2027 Alnylam Pharmaceuticals, the leading RNAi therapeutics company, announced today that it has entered into separate, privately negotiated repurchase…











